The first patients in Denmark with benign prostatic hyperplasia have now been successfully treated using ProstaLund’s new CoreTherm® Eagle. The treatments were carried out at Gentofte Hospital, marking the first clinic outside Sweden to adopt the new platform – a significant milestone in the international rollout.
“We are excited to see our first clinic outside Sweden now up and running with CoreTherm® Eagle. The successful treatments of the first patients in Denmark mark yet another important milestone in our continued rollout. Next step is to expand beyond the Nordic region, bringing the benefits of CoreTherm® Eagle to a broader international market,” says Malin Melander, acting CEO and COO at ProstaLund.
“We have now started treatment with the new CoreTherm® Eagle and everything has gone beyond expectations,” says Dr. Lilli Winck-Flyvholm, Senior Consultant in Urology at Gentofte Hospital.
CoreTherm® Eagle builds on more than 25 years of clinical experience from earlier CoreTherm® platforms, used in over 30,000 treatments for benign prostatic hyperplasia. The new platform includes major technical advancements, such as automated calculation of treatment goals and an improved user interface, providing increased support and ease of use for healthcare professionals.